Who
Louis G. Lange
Director
Company insider
Files Form 4 as: Director, NewAmsterdam Pharma Company; Director, Audentes Therapeutics; Director, CymaBay Therapeutics; Director, Esperion Therapeutics; Director, Maxygen; EVP Cardiovascular Therapeutic, Gilead Sciences; Chairman & CEO, Cv Therapeutics.
In numbers
- Trades disclosed
- 273
- Buys
- 2
- Sells
- 16
- Bought
- $294K
- Sold
- $23.3M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 22 Dec 2005
- Last trade
- 11 Mar 2026
- Last filed
- 12 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Mar 2026filed 12 Mar 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $1.3M44,173 at $30.41 | filing |
| 11 Mar 2026filed 12 Mar 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $14K446 at $31.23 | filing |
| 11 Mar 2026filed 12 Mar 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $1.3M44,173 at $30.41 | filing |
| 11 Mar 2026filed 12 Mar 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $14K446 at $31.23 | filing |
| 9 Mar 2026filed 10 Mar 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code X | $513K44,619 at $11.50 | filing |
| 9 Mar 2026filed 10 Mar 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code X | —44,619 at $0.00 | filing |
| 9 Mar 2026filed 10 Mar 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code X | —44,619 at $0.00 | filing |
| 9 Mar 2026filed 10 Mar 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code X | $513K44,619 at $11.50 | filing |
| 6 Mar 2026filed 10 Mar 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $829K28,186 at $29.41 | filing |
| 6 Mar 2026filed 10 Mar 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $829K28,186 at $29.41 | filing |
| 7 Jan 2026filed 9 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code A | —3,400 | filing |
| 7 Jan 2026filed 9 Jan 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,300 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,300 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code A | —3,400 | filing |
| 1 Jun 2025filed 3 Jun 2025 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —68 | filing |
| 1 Jun 2025filed 3 Jun 2025 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | —68 at $0.00 | filing |
| 1 May 2025filed 2 May 2025 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —69 | filing |
| 1 May 2025filed 2 May 2025 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | —69 at $0.00 | filing |
| 14 Apr 2025filed 21 Apr 2025 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —69 | filing |
| 14 Apr 2025filed 21 Apr 2025 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | —69 at $0.00 | filing |
News
Head-To-Head Analysis: Rallybio (NASDAQ:RLYB) versus NewAmsterdam Pharma (NASDAQ:NAMS)NAMS · dailypolitical.com · 14 Oct 2026Analyzing NewAmsterdam Pharma (NASDAQ:NAMS) & Grifols (NASDAQ:GRFS)NAMS · tickerreport.com · 14 Oct 2026Financial Analysis: NewAmsterdam Pharma (NASDAQ:NAMS) versus Rallybio (NASDAQ:RLYB)NAMS · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Louis G. Lange; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.